Skip to content

Blood Neurotrophic Factors in Adults

Blood Neurotrophic Factors in Adults

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00505349
Enrollment
0
Registered
2007-07-23
Start date
2007-06-30
Completion date
2009-06-30
Last updated
2016-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

neurotrophic factors, cognitive status, young adults, mature adults, cognitive training

Brief summary

The overall goal of this study is to evaluate the impact of cognitive training on blood levels of neurotrophic factors in adults.

Detailed description

Current research suggests that levels of brain-derived neurotrophic factor (BDNF) and certain excitatory neurotransmitters - specifically glutamate, D-serine, and glycine are low in participants with depression and other mental illnesses (Wolkowitz and Reus 2002, Tan et al., 2005; Shoval & Weizman, 2005; Hashimoto et al., 2005). Research also suggests that levels of both BDNF and excitatory transmitters can be enhanced by cognitive stimulation (Hynd et al., 2005; Wu et al., 2005; Yang et al., 2005; Mattson et al., 2004). BDNF is found in brain tissue and is also measurable in blood; it stimulates neuronal cell growth in certain brain regions (Duman, 2004). In Phase 1, we wish to measure the levels of specific neurotrophic factors in healthy, young participants. Phase 2 is intended to correlate similar levels with change in neurocognitive performance in healthy, older participants. Overall, this study is designed to obtain a raw measure of the impact that cognitive training has on the mature adult brain.

Interventions

The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)

Sponsors

University of California, San Francisco
CollaboratorOTHER
Case Western Reserve University
CollaboratorOTHER
Posit Science Corporation
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Phase 1: Closed * Age 18-30 at the time of consent * Good general medical health * Willing to undergo venipuncture procedure Phase 2: Activation Pending * Age 65 or older at the time of consent * Mini-Mental Status Examination (MMSE) score of 26 or higher * Willing to undergo venipuncture procedure * Fluency in the English language * Participant is willing and able to commit to the time requirement of the study

Exclusion criteria

Phase 1 * Participant is experiencing chronic or acute illness * Current substance abuse, including alcoholism * Diagnosis of a major psychological disorder * Current use, or use within the past 3 months of medications specified by protocol * Participant is unwilling or unable to perform questionnaires as specified in the protocol * Participant is not capable of giving informed consent or is unable to comprehend and/or follow directions in English * Participant is enrolled in a concurrent clinical study that could affect the outcome of this study * Female only: Participant is pregnant Phase 2 Sensory/Motor Exclusions: * Reported or observed difficulties with a participant's dominant hand Psychiatric Exclusions: * Current diagnosis of a major psychological disorder or a psychiatric hospitalization * Current substance abuse, including alcoholism Neurological Exclusions: * Current diagnosis of a major neurological disorder that may impact cognitive functioning * History of stroke, traumatic brain injury (leading to loss of consciousness), brain cancer, or invasive neurological procedure within the past year * Diagnosis of medically uncontrolled seizure disorder Medication Exclusions: * Current use, or use within the past 3 months of medications specified within the investigational plan Additional Exclusions: * Participant is unwilling or unable to perform assessments and/or evaluations as specified in the protocol * Participant is not capable of giving informed consent or is unable to comprehend and/or follow directions * Participant is enrolled in a concurrent clinical study that could affect the outcome of this study

Design outcomes

Primary

MeasureTime frame
The primary outcome of this study will be the evaluation of blood derived neurotrophic factors in both young adults and in mature adults undergoing cognitive training.Up to 14 weeks post-enrollment

Secondary

MeasureTime frame
To obtain information on the levels of growth factors in health adultsRequired blood draws at three study intervals

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026